OncotypeDx for breat cancer – pro
The Oncotype DX Breast Recurrence Score® test provides a score that can be used to evaluate the need for and efficacy of adjuvant chemotherapy for early-stage HR+, HER2- breast cancer patients. Recurrence Score® result assesses the expression of 21 genes—16 cancer-related genes and 5 reference genes—in a tumor sample using reverse transcription polymerase chain reaction (RT-PCR). The 12-year results of the Trial Assigning IndividuaLized Options for Treatment (Rx) (TAILORx) identified 85% of women with early-stage, node-negative breast cancer who may receive no benefit from chemotherapy and 15% for whom chemotherapy can be life-saving. ESMO and NCCN recommend tis test in their guidelines.
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-1220.
NCCN Breast Cancer 2024 BINV-7
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-1546.